AR017851A1 - Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape - Google Patents

Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape

Info

Publication number
AR017851A1
AR017851A1 ARP980106321A ARP980106321A AR017851A1 AR 017851 A1 AR017851 A1 AR 017851A1 AR P980106321 A ARP980106321 A AR P980106321A AR P980106321 A ARP980106321 A AR P980106321A AR 017851 A1 AR017851 A1 AR 017851A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
statin
composition
carboxialchylical
eter
Prior art date
Application number
ARP980106321A
Other languages
English (en)
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR017851A1 publication Critical patent/AR017851A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ARP980106321A 1997-12-12 1998-12-11 Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape AR017851A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
AR017851A1 true AR017851A1 (es) 2001-10-24

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106321A AR017851A1 (es) 1997-12-12 1998-12-11 Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape

Country Status (30)

Country Link
EP (1) EP1045691B1 (https=)
JP (1) JP2002508320A (https=)
KR (1) KR20010033003A (https=)
AR (1) AR017851A1 (https=)
AT (1) ATE285762T1 (https=)
AU (1) AU754089B2 (https=)
BR (1) BR9813542A (https=)
CA (1) CA2304612A1 (https=)
CO (1) CO4970816A1 (https=)
CR (1) CR5926A (https=)
CU (1) CU20000140A7 (https=)
DE (1) DE69828442T2 (https=)
DK (1) DK1045691T3 (https=)
ES (1) ES2230733T3 (https=)
GT (1) GT199800196A (https=)
HN (1) HN1998000185A (https=)
HU (1) HUP0004547A3 (https=)
IL (1) IL135349A0 (https=)
IS (1) IS2150B (https=)
MY (1) MY118381A (https=)
NO (1) NO20002966D0 (https=)
NZ (1) NZ503982A (https=)
PA (1) PA8464601A1 (https=)
PE (1) PE20000017A1 (https=)
PL (1) PL341066A1 (https=)
PT (1) PT1045691E (https=)
SV (1) SV1998000146A (https=)
UY (1) UY25299A1 (https=)
WO (1) WO1999030704A1 (https=)
ZA (1) ZA9811348B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
EP1037623A1 (en) * 1997-12-12 2000-09-27 Warner-Lambert Company Antihyperlipidemic statin-lp(a) inhibitor combinations
YU23901A (sh) * 1998-09-30 2003-07-07 Warner-Lambert Company Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (https=) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
SK10622002A3 (sk) 2000-01-25 2003-07-01 Warner-Lambert Company Étery dikarboxylátu vápenatého, metódy ich výroby a ich využitie na liečbu vaskulárnych chorôb a diabetu
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
EP1280522B1 (en) * 2000-04-26 2004-12-01 Warner-Lambert Company Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
US6689807B1 (en) 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
MX367352B (es) * 2012-01-06 2019-08-16 Gemphire Therapeutics Inc Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
HK1257929A1 (zh) * 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
NZ503982A (en) 2002-03-28
BR9813542A (pt) 2000-10-10
NO20002966L (no) 2000-06-09
DE69828442T2 (de) 2005-06-02
UY25299A1 (es) 2001-08-27
DK1045691T3 (da) 2005-03-14
EP1045691A1 (en) 2000-10-25
PE20000017A1 (es) 2000-01-20
AU754089B2 (en) 2002-11-07
IL135349A0 (en) 2001-05-20
WO1999030704A1 (en) 1999-06-24
ES2230733T3 (es) 2005-05-01
ATE285762T1 (de) 2005-01-15
MY118381A (en) 2004-10-30
IS2150B (is) 2006-10-13
CO4970816A1 (es) 2000-11-07
CR5926A (es) 2000-03-06
SV1998000146A (es) 1999-09-30
IS5445A (is) 2000-04-14
PL341066A1 (en) 2001-03-26
GT199800196A (es) 2000-06-03
JP2002508320A (ja) 2002-03-19
PT1045691E (pt) 2005-03-31
CA2304612A1 (en) 1999-06-24
HN1998000185A (es) 1999-06-02
DE69828442D1 (de) 2005-02-03
ZA9811348B (en) 1999-06-14
PA8464601A1 (es) 2001-12-14
NO20002966D0 (no) 2000-06-09
KR20010033003A (ko) 2001-04-25
AU1591599A (en) 1999-07-05
CU20000140A7 (es) 2005-10-19
HUP0004547A3 (en) 2001-12-28
EP1045691B1 (en) 2004-12-29
HUP0004547A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
AR017851A1 (es) Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
ATE181551T1 (de) Taxol-derivate
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
AR003937A1 (es) Compuesto ciclico que tiene efecto antagonico al receptor de taquiquinina, proceso para producirlo y composicion farmaceutica que lo contiene.
EA199900620A1 (ru) Фталазиноны
ATE283051T1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
CY1109153T1 (el) Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
BR9711586A (pt) Compostos e uso dos mesmo
AR046970A1 (es) Esteres de fosfato de florfenicol
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
ES2172083T3 (es) Composicion limpiadora antibacteriana ultrasuave para uso frecuente.
AR005147A1 (es) Una solución farmacéutica acuosa inyectable que comprende danofloxacina o una de sus sales farmacéuticamente aceptables y su uso.
ATE222115T1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
CY1105575T1 (el) Ενωσεις αμιδιου και χρηση αυτων
ES2167931T3 (es) Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen.
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AR015945A1 (es) Composiciones de spray para el cabello autofobicas
HN2001000235A (es) Derivados puentes de piperazina
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
NO20033184L (no) Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
BR0111767A (pt) Composições analgésicas e anti-inflamatórias contendo inibidores de cox-2, seu uso e método para potencializar um composto analgésico

Legal Events

Date Code Title Description
FB Suspension of granting procedure